Clinical Significance of Tumor-infiltrating Lymphocytes for Gastric Cancer in the Era of Immunology

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2017 Aug 16

PMID 28808502

Citations 38

Authors

Byung Woog Kang

Jong Gwang Kim

In Hee Lee

Han Ik Bae

An Na Seo

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has begun to revolutionize cancer treatment, by introducing therapies that target the host immune system instead of the tumor, therapies that possess unique adverse event profiles, and therapies that may cure certain types of cancer. The immune microenvironment of tumors is emerging as the most important means of understanding the relationship between a patient' immune system and their cancer, informing prognosis, and guiding immunotherapy, such as an antibody blockade of immune checkpoints. For some solid tumors, simple quantitation of lymphocyte infiltration would seem to have prognostic significance, suggesting that lymphocyte infiltration is not passive but may actively promote or inhibit tumor growth. For gastric cancers, several studies have provided strong evidence that immune cells contribute to determining prognosis. However, the exact role of immune cells in gastric cancer remains unclear. Therefore, this review focuses on the clinical significance of immune cells, especially tumor-infiltrating lymphocytes, in gastric cancer.

Citing Articles

Zhang Z, Zhang W, Liu X, Yan Y, Fu W Oncol Lett. 2024; 28(5):537.

PMID: 39319215 PMC: 11421013. DOI: 10.3892/ol.2024.14670.

Low Absolute Lymphocyte Count Correlates with Lymph Node Metastases and Worse Survival of Patients with Gastric Cancer.

Jung Y, Kim S, Seo H, Lee H, Song K, Kim S Ann Surg Oncol. 2024; 31(10):6951-6958.

PMID: 39090494 DOI: 10.1245/s10434-024-15874-w.

Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma.

Yavuz A, Simsek K, Alpsoy A, Altunay B, Gedik E, Unal B World J Gastrointest Pathophysiol. 2024; 15(1):91237.

PMID: 38682027 PMC: 11045359. DOI: 10.4291/wjgp.v15.i1.91237.

The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy.

Pan Y, Ma Y, Dai G Nutrients. 2023; 15(19).

PMID: 37836573 PMC: 10574242. DOI: 10.3390/nu15194290.

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022.

Chen Y, Chen Y, Tan S, Zheng Y, Liu S, Zheng T Hum Vaccin Immunother. 2023; 19(1):2186684.

PMID: 37017186 PMC: 10088978. DOI: 10.1080/21645515.2023.2186684.

References

Choi H, Ha S, Kim H, Ahn S, Kang M, Kim K . The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget. 2016; 7(7):7940-51. PMC: 4884965. DOI: 10.18632/oncotarget.6958. View

Chiaravalli A, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R . Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2005; 448(3):344-53. DOI: 10.1007/s00428-005-0066-4. View

Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H . Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000; 88(3):577-83. View

Liu K, Yang K, Wu B, Chen H, Chen X, Chen X . Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015; 94(39):e1631. PMC: 4616881. DOI: 10.1097/MD.0000000000001631. View

Palucka A, Coussens L . The Basis of Oncoimmunology. Cell. 2016; 164(6):1233-1247. PMC: 4788788. DOI: 10.1016/j.cell.2016.01.049. View

Rosso D, Rigueiro M, Kassab P, Ilias E, Castro O, Novo N . [Correlation of natural killer cells with the prognosis of gastric adenocarcinoma]. Arq Bras Cir Dig. 2013; 25(2):114-7. DOI: 10.1590/s0102-67202012000200011. View

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T . Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol. 2010; 102(7):742-7. DOI: 10.1002/jso.21725. View

Liu T, Peng L, Yu P, Zhao Y, Shi Y, Mao X . Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012; 32(6):1332-9. DOI: 10.1007/s10875-012-9718-8. View

10.

Chang W, Du Y, Zhao X, Ma L, Cao G . Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 2014; 20(16):4586-96. PMC: 4000495. DOI: 10.3748/wjg.v20.i16.4586. View

11.

Liu X, Yang Z, Latchoumanin O, Qiao L . Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therap Adv Gastroenterol. 2016; 9(6):853-860. PMC: 5076768. DOI: 10.1177/1756283X16658251. View

12.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

13.

Park J, Kwon M, Shin E . Immune checkpoint inhibitors for cancer treatment. Arch Pharm Res. 2016; 39(11):1577-1587. DOI: 10.1007/s12272-016-0850-5. View

14.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

15.

Zhang M, Dong Y, Liu H, Zhao S, Xuan Q, Wang Y . The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep. 2016; 6:37933. PMC: 5124943. DOI: 10.1038/srep37933. View

16.

Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H . Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003; 9(12):4404-8. View

17.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

18.

Zhou S, Shen Z, Wang Y, Ma H, Xu S, Qin J . CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One. 2013; 8(9):e74430. PMC: 3764061. DOI: 10.1371/journal.pone.0074430. View

19.

Lee H, Chae S, Lee Y, Kim M, Lee H, Lee B . Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008; 99(10):1704-11. PMC: 2584941. DOI: 10.1038/sj.bjc.6604738. View

20.

Lee K, Hwang H, Nam K . Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. Gut Liver. 2014; 8(2):131-9. PMC: 3964262. DOI: 10.5009/gnl.2014.8.2.131. View